Lilly sues six sellers over a $200-a-month black market in shots billed as its obesity drug
Med spas and online sellers are moving retatrutide at about $200 a month while it is still in phase 3, against an estimated $1,000 to $1,500 approved list price. Lilly has sued six US sellers to clear the market before its first-quarter 2027 filing.
Vincent Jiang · 2 min read
Six lawsuits over a drug that is not for sale
Med spas and online sellers are moving shots billed as retatrutide at roughly $200 a month, pitched as a weight-loss "hack" 1. The molecule is still in phase 3, and no regulator anywhere has approved it for human use, Lilly−0.28% — Lilly, down 0.28 percent today says 2. Selling it is illegal, so on August 12, 2026 Lilly sued six US businesses, among them Aesthetic Envy Cosmetic Centers, Striker Pharmacy and Texas Peptides, in California and Texas courts 2.
The FDA has said retatrutide cannot lawfully be compounded or sold 5. Lilly's chief medical officer, David Hyman, calls the street product "entirely unverified, unapproved and not worth the risk" 2.
What Lilly is defending
The molecule is worth the lawsuits. In the TRIUMPH-1 phase 3 extension, patients with severe obesity lost up to 30.3% of body weight over 104 weeks on the highest dose 3. Lilly will file for approval in the first quarter of 2027, later than first planned, citing manufacturing and quality data 4. Analysts see nearly $4 billion in 2030 sales 1.
14,000 listings, 200 referrals, 90,000 vials
Lilly says it has reported more than 14,000 websites, ads and listings in over 100 countries, and referred more than 200 people and entities to the FDA and the Justice Department 5. The FDA has warned sellers that "research use only" labels do not hide marketing aimed at humans 6. Customs intercepted 690 shipments holding 31,000 units of illicit GLP-1s in fiscal 2025, and nearly 90,000 vials in July alone 1. The DOJ has indicted a counterfeit Ozempic ring supplied from China 7.
The switch nobody can price
The gap Lilly must close: $200 street vials against a $1,000-plus launch price
- Estimate
Data
| Value | |
|---|---|
| Black-market street price | $200/mo |
| Approved list, low estimate (estimate) | $1,000/mo |
| Approved list, high estimate (estimate) | $1,500/mo |
Street buyers are anchored near $200 a month, against a list price MMIT chief clinical officer Jayne Hornung estimates at $1,000 to $1,500 1. A fifth of GLP-1 users are outside the FDA's fence, and 12 percent cannot say which side they are on, Gallup finds 1. The 2030 estimates only clear if those patients resurface at list price, five to seven times what they pay today.
The tape shows no damage yet
RBC expects Lilly to raise full-year revenue guidance at the Q3 report on diabetes and weight-loss momentum 8, and quarterly revenue has doubled since late 2024 9.
Lilly's quarterly revenue has doubled since late 2024 on GLP-1 demand
Data
| Revenue | |
|---|---|
| Q3 '24 | $11.44B |
| Q4 '24 | $13.53B |
| Q1 '25 | $12.73B |
| Q2 '25 | $15.56B |
| Q3 '25 | $17.6B |
| Q4 '25 | $19.29B |
| Q1 '26 | $19.8B |
| Q2 '26 | $22.97B |
The market for compounded GLP-1s narrowed once shortages ended 1, which is the bull case for enforcement. That fight was over copies of an approved drug; this one formed before approval existed. Watch the Q3 print, the first-quarter 2027 filing, and the number nobody has yet: how many $200-a-month patients reappear at list price.
Deepdive
AI-generated from this story and its cited sources. Not investment advice.
